Unethical Experiments
September 25, 2002 NIH suspended ARDS Lung experiment in Aug / AHRP filed complaint re: ARDS in July FYI On July 29, 2002 The Alliance for Human Research Protection (AHRP) filed a complaint with the federal Office of Human Research Protections (OHRP), expressing ethical and methodological concerns about an acute…
Federal Investigation of ARDS Study (Accute Respiratory Distress) OHRP conducted a compliance oversight evaluation of the 12 major sites participating in this clinical trial. OHRP’s determination letters documenting the outcomes of these evaluations can be viewed at the OHRP website at the following URLs: Note: OHRP found that federal informed…
OHRP Investigation of experimental treatment for Acute Respiratory Distress Syndrome. ARDSNet studies: ARMA, FACCT, and ALVEOLI Table of Contents to Fax from OHRP page 1 Oct. 7, 2002 OHRP letter to: Ronald S. Newvbower, Ph.D(Mass. General Hospital), Lee E. Limbird, Ph.D. (Vanderbilt University), and Robert Kay, MD) (Cleveland Clinic Foundation)…
AHRP Letter to Editor re: ARDS published NEJM Fri, 11 Jul 2003 A truncated version of a Letter to the editor submitted by John H. Noble, Jr., PhD and Vera Sharav appears in the current July 10, 2003, issue of The New England Journal of Medicine. Note: On April 3,…
Commentary by Vera Hassner Sharav February 18, 2002Â FYI United States Government Sponsored Genetic Research in Rural China Raises Troubling Ethical Concerns A January 2002 report in China Daily, byXiong Lei, the senior journalist with China Features, Xinhua News Agency(below), raises troubling ethical concerns about U.S. government-sponsoredgenetic research in rural…
THE ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) 142 West End Ave, Suite 28P New York, NY 10023 212-595-8974 ahrp@researchprotection.org September 4, 2002 Michael Carome, MD Associate Director for Regulatory Affairs Office for Human Research Protections The Tower Building 1101 Wootton Parkway, Suite 200 Rockville, Maryland 20852 Re: Acute Respiratory Distress…
An editorial in today's New York Times is a follow-up to its riveting report by Ian Urbina on the recommendation by an Institute of Medicine panel to
lift 1978 federal restrictions on medical experiments on prisoners. http://www.nytimes.com/2006/08/13/us/13inmates.html?
Stanford University researchers used 61 inmates ranging in age from 14 to 18 at a California Youth Authority (CYA) correctional center in an experiment testing the psychotropic drug, Depakote.
Tune in tonight–Monday– to Court TV: the subject is medical experimentation on prisoners–What does this say about our moral climate?
The full impact on six healthy volunteers who took part in a catastrophic experiment that nearly killed them is ever so slowly coming to light.
BBC reports: "TeGenero, a German pharmaceutical company, said it could not continue in business.Because of the fallout from the UK trial, it was impossible to attract investment, TeGenero said."
One day following a rport in The New York Times, Sanifo-Aventis, manufacturer of Ketek, suspended the trial in children. The FDA has not announced any action.
